The Effect of Nalbuphine Extended-Release (NAL ER) on Cough in Participants With Refractory Chronic Cough (RCC)

Inclusion Criteria: * Meets society guideline-based criteria for a diagnosis of RCC defined as: * Insufficient improvement in cough after treatment for any identified cough-associated conditions. * Unexplained cough for which an underlying condition has not been determined despite adequate investigation with diagnostic tests and trials of therapy. * Persistent and chronic cough for at least one year prior to Screening. * Chest computed tomography (CT) or chest radiograph of the thorax performed within the last 24 months and after the onset of chronic cough OR the procedure completed by the Investigator during the Screening period, that does not show any abnormality considered to be significantly contributing to the RCC in the opinion of the Principal Investigator. * 24-hour objective cough frequency ≥10 coughs/hour based on VitaloJAK® cough monitor recording performed during the Screening and Placebo Run-in Periods as well as a minimum recording duration of 20 hours suitable for analysis during the placebo Run-in assessment. * Forced expiratory volume in 1 second (FEV1) /forced vital capacity (FVC) ratio ≥ 60% as determined by spirometry adhering to American Thoracic Society (ATS)/European Respiratory Society (ERS) guidelines. Exclusion Criteria: * Clinical diagnosis of sleep apnea and/or use of continuous positive airway pressure (CPAP). * Upper or lower respiratory tract infection or change in pulmonary status in the 4 weeks prior to the Screening visit or during th…